Intensity-modulated radiation therapy versus three-dimensional conformal radiation therapy with concurrent nedaplatin-based chemotherapy after radical hysterectomy for uterine cervical cancer: Comparison of outcomes, complications, and dose-volume histogram parameters

Radiation Oncology

Volumn 10, Issue 1, 2015, Pages

  Isohashi, Fumiaki ^a   Mabuchi, Seiji ^a   Yoshioka, Yasuo ^a   Seo, Yuji ^a   Suzuki, Osamu ^a   Tamari, Keisuke ^a   Yamashita, Michiko ^a   Unno, Hikari ^a   Kinose, Yasuto ^a   Kozasa, Katsumi ^a   Sumida, Iori ^a   Otani, Yuki ^a   Kimura, Tadashi ^a   Ogawa, Kazuhiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NEDAPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HISTOGRAM; HUMAN; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADICAL HYSTERECTOMY; UTERINE CERVIX CANCER; ADVERSE EFFECTS; CHEMORADIOTHERAPY; CONFORMAL RADIOTHERAPY; DISEASE FREE SURVIVAL; HYSTERECTOMY; KAPLAN MEIER METHOD; MIDDLE AGED; PROCEDURES; RADIOTHERAPY PLANNING SYSTEM; RETROSPECTIVE STUDY; UTERINE CERVICAL NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYSTERECTOMY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 84939808061     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/s13014-015-0486-5     Document Type: Article

References (22)

1. Peters WA 3rd, Liu PY, Barret RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage caner of the cervix. J Clin Oncol. 2000;18:1606-13.
2. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73:177-83.
3. Ryu SY, Park SI, Nam BH, Cho CK, Kim K, Kim BJ, et al. Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors? Int J Radiat Oncol Biol Phys. 2011;79:794-9.
4. Isohashi F, Yoshioka Y, Mabuchi S, Konishi K, Koizumi M, Takahashi Y, et al. Dose-volume histogram predictors of chronic gastrointestinal complications after radical hysterectomy and postoperative concurrent nedaplatin-based chemoradiation therapy for early-stage cervical cancer. Int J Radiat Oncol Biol Phys. 2013;85:728-34.
5. Mabuchi S, Morishige K, Isohashi F, Yoshioka Y, Takeda T, Yamamoto T, et al. Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors. Gynecol Oncol. 2009;115:482-7.
6. Okazawa M, Mabuchi S, Isohashi F, Suzuki O, Yoshioka Y, Sasano T, et al. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience. Int J Gynecol Cancer. 2013;23:567-75.
7. Mabuchi S, Okazawa M, Isohashi F, Ohta Y, Maruoka S, Yoshioka Y, et al. Postoperative whole pelvic radiotherapy plus concurrent chemotherapy versus extended-field irradiation for early-stage cervical cancer patients with multiple pelvic lymph node metastases. Gynecol Oncol. 2011;120:94-100.
8. Mabuchi S, Takahashi R, Isohashi F, Yokoi T, Ito K, Tsutui T, et al. A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodes. Int J Gynecol Cancer. 2013;23:1279-86.
9. Small W Jr, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71:428-34.
10. Japan Clinical Oncology Group, Toita T, Ohno T, Kaneyasu Y, Uno T, Yoshimura R, et al. A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer. Jpn J Clin Oncol. 2010;40:456-63.
11. Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:1356-65.
12. Chen MF, Tseng CJ, Tseng CC, Kuo YC, Yu CY, Chen WC. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1438-44.
13. Folkert MR, Shih KK, Abu-Rustum NR, Jewell E, Kollmeier MA, Makker V, et al. Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer. Gynecol Oncol. 2013;128:288-93.
14. Mabuchi S, Kimura T. Nedaplatin: a radiosensitizing agent for patients with cervical cancer. Chemother Res Pract. 2011;2011:963159.
15. Kobayashi Y, Ohara T, Wada Y, Okuda Y, Kondo H, Okuma Y, et al. Concurrent chemoradiotherapy with nedaplatin after radical hysterectomy in patients with stage IB and II cervical cancer. J Obstet Gynaecol Res. 2009;35:490-4.
16. Niibe S, Tsunoda T, Jobo T, Imai M, Matsuo K, Matsunaga K, et al. Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma (LAUCC): Kitasato Gynecologic Radiation Oncology Group (KGROG 0501): initial analysis. Eur J Gynaecol Oncol. 2008;29:222-4.
17. Chopra S, Dora T, Chinnachamy AN, Thomas B, Kannan S, Engineer R, et al. Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study. Int J Radiat Oncol Biol Phys. 2014;88:630-5.
18. Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Ten Haken RK, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys. 2010;76 Suppl 3:S101-7.
19. Wedlake LJ, Thomas K, Lalji A, Blake P, Khoo VS, Tait D, et al. Predicting late effects of pelvic radiotherapy: is there a better approach? Int J Radiat Oncol Biol Phys. 2010;78:1163-70.
20. Klopp AH, Moughan J, Portelance L, Miller BE, Salehpour MR, Hildebrandt E, et al. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys. 2013;86:83-90.
21. Albuquerque K, Giangreco D, Morrison C, Siddiqui M, Sinacore J, Potkul R, et al. Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT. Int J Radiat Oncol Biol Phys. 2011;79:1043-7.
22. Bazan JG, Luxton G, Kozak MM, Anderson EM, Hancock SL, Kapp DS, et al. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2013;87:983-91.